This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bulotta, A. Articles by Trischitta, V. Search for Related Content PubMed PubMed Citation Articles by Bulotta, A. Articles by Trischitta, V. Related Collections Diabetes and Insulin

The Common –866G/A Polymorphism in the Promoter Region of the UCP-2 Gene Is Associated with Reduced Risk of Type 2 Diabetes in Caucasians from Italy

Unit of Endocrinology, Scientific Institute Casa Sollievo della Sofferenza (A.B., O.L., A.C., R.D.P., V.T.), San Giovanni Rotondo, Italy; Unit of Genetics, Scientific Institute Casa Sollievo della Sofferenza (A.Q., M.C.), San Giovanni Rotondo, Italy; Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud (F.P.), S. Maria Imbaro, Italy; Casa Sollievo della Sofferenza-Mendel Institute (S.P., V.T.), Rome, Italy; and Department of Clinical Sciences, University La Sapienza (V.T.), Rome, Italy

Address all correspondence and requests for reprints to: Dr. Angela Bulotta, Unit of Endocrinology, Scientific Institute Casa Sollievo della Sofferenza, Poliambulatorio Giovanni Paolo II, Viale Padre Pio, 71013 San Giovanni Rotondo (FG), Italy. E-mail: a.bulotta{at}operapadrepio.it.

	Abstract

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Uncoupling protein-2 (UCP2) regulates insulin secretion and may play an important role in linking obesity to type 2 diabetes (T2D). Previous studies of the role of the UCP2 promoter –866G/A single nucleotide polymorphisms (SNP) in T2D have given opposite results. We tested the distribution of the –866G/A SNP in 746 T2D patients and 327 healthy unrelated Caucasians from Italy. We also tested for an effect of the P12A variant of the peroxisomal proliferator-activated receptor-2 (PPAR2) gene on diabetes risk given by the UCP2 SNP. Compared with –866G/G carriers, a progressively reduced (P = 0.01) risk of T2D was observed in –866G/A and –866A/A subjects, with the latter showing an approximately 50% risk reduction [odd ratio (OR), 0.51; 95% confidence interval (CI), 0.3–0.8; P = 0.003]. Conversely, the –866G/G genotype was associated with increased risk (OR, 1.31; 95% CI, 1.01–1.71). Overall, the population risk attributable to the UCP2 –866G/G genotype was about 12%. After stratifying for the PPAR2 polymorphism, the increased risk conferred by the UCP2 G/G genotype was still evident among P12/P12 homozygous subjects (n = 801; OR, 1.38; 95% CI, 1.04–1.83), but seemed to disappear among the X12/A12 subjects (i.e. P12/A12 heterozygous or A12/A12 homozygous subjects; n = 137; OR, 0.87; 95% CI, 0.40–1.91). Whether this apparent difference is entirely due to the different number of carriers of the two PPAR2 genotypes is a likely possibility that deserves deeper investigation. In conclusion, in our population, the –866G/A SNP is associated with T2D. Additional studies in larger samples are needed to investigate the possibility of a concomitant effect of modifier genes such as PPAR2.

	Introduction

Top Abstract Introduction Subjects and Methods Results Discussion References

 
TYPE 2 DIABETES (T2D) and its cardiovascular complications are a tremendous burden on health care systems (1). The combination of insulin resistance and reduced pancreatic ß-cell function are pathogenic for T2D (2). Both defects are likely to be under polygenic control, with several genes simultaneously involved (3).

Uncoupling protein 2 (UCP2) belongs to the superfamily of the mitochondrial transporter proteins and is highly expressed in adipose tissue and pancreatic islets (4). By uncoupling ß-cell metabolism from ATP generation, UCP2 has been reported to negatively regulate glucose-stimulated insulin secretion (5). UCP2 is, in fact, overexpressed in islets of ob/ob mice, a model of obesity-induced diabetes (6); conversely, when knocking out the UCP2 gene, these mice may be partially rescued from diabetes as a consequence of increased insulin secretion (6). At variance, other studies have reported that in a different model of obesity-induced T2D (i.e. Zucker diabetic fat rats) UCP2 overexpression may favor ß-cell function and eventually improve glycemic control (7). Although suggesting an opposite effect, both reports (6, 7) clearly indicate that UCP2 may play an important role in linking obesity to ß-cell dysfunction and T2D.

In the Goto-Kazizaki rat, the UCP2 gene is linked to D1Wox38 marker (8) (at 87.9 cM of the rat chromosome 1, www.well.ox.ac.uk/rat_mapping_resources/), which is located in a region where a relevant number of linkage peaks for glucose intolerance and adiposity have been identified (8). In humans, the 11q13 chromosomal region (which contains the UCP2 gene) is weakly linked to T2D in Finns (9), but not in other populations (10). In Finns, by a genome scan performed at an average resolution of 8 cM, the most relevant logarithm of the odds (LOD) score peak in 11q13, lies about 8 cM from the UCP2 gene locus (9).

Taken together, all of these data indicate that the UCP2 gene is an excellent candidate for T2D. A functional –866 G/A single nucleotide polymorphism (SNP) has been described in the UCP2 promoter (11). The –866 A allele has been reported to increase UCP2 transcriptional activity in transfected cultured cells (12); however, data in human tissues have been conflicting, reporting either increased (12) or decreased (13) UCP2 mRNA levels to be associated with the –866 A allele. Finally, despite the fact that the –866A allele is associated with reduced insulin secretion in nondiabetic individuals (14), its role in T2D has been contradictory, with A allele carriers reported to be at increased (12) or reduced (13) risk. According to the polygenic model proposed for T2D (3), this latter discrepancy might be partly due to the concomitant and confounding effects of modifier genes. Among the genetic variants with a broad impact on the risk of T2D is the highly prevalent P12A polymorphism of the peroxisomal proliferator-activated receptor-2 (PPAR2) gene that encodes for a transcription factor involved in the regulation of adipocyte differentiation and intracellular insulin signaling (15, 16, 17). The common PPAR2 P12A variant is associated with the risk of T2D (15, 18). Interestingly, PPAR2 modulates UCP2 expression (19, 20). In addition, both agonists and antagonists of the PPAR effect modulate insulin secretion (20, 21, 22, 23). Together these data (19, 20, 21, 22, 23) make the possibility of a combined effect of the two genes on the risk of T2D a likely one.

In the present study we evaluated the association of the common –866G/A SNP of the UCP2 gene with T2D in a Caucasian population from Gargano (east coast of central Italy). We also tested for an effect of the P12A variant of the PPAR2 gene on the diabetes risk conveyed by the UCP2 SNP.

	Subjects and Methods

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Experimental subjects

Both cases and controls were of Caucasian origin and resident of the same region (i.e. Gargano and surrounding areas, east coast of central Italy). Cases were 746 (382 men and 364 women) patients with T2D consecutively recruited from the Endocrine Unit at Scientific Institute CSS (San Giovanni Rotondo, Italy) who met the following criteria: 1) diabetes diagnosed after 30 yr, 2) insulin treatment not required for at least 2 yr after diabetes diagnosis, and 3) absence of clinically evident autoimmune disease. The clinical features of patients studied are shown in Table 1. To quantify the risk of recruiting late-onset type 1 diabetic patients, anti-glutamic acid decarboxylase antibodies were determined in 200 randomly selected patients: only three of 200 patients were antiglutamic acid decarboxylase positive (>0.9 U/ml), indicating that the risk of misdiagnosis is trivial in our sample. The control group consisted of 327 (116 men and 211 women) unrelated subjects with the same age range (35–76 yr) as cases who were recruited in the same area as part of an ongoing study of the genetics of insulin resistance. Selection criteria were as follows: fasting plasma glucose less than 6.1 mmol/liter, no medications known to affect glucose and lipid metabolism, and absence of systemic diseases. Clinical features of control subjects are shown in Table 2. A family history of diabetes was not a selection criterion in either T2D and controls. All subjects enrolled in the study underwent physical examination, including measurements of height, weight, and blood pressure, as previously described (24). Venous blood of all fasting subjects was sampled from an antecubital vein for measurements of glucose, insulin, total and high density lipoprotein cholesterol and triglycerides, and hemoglobin A_1c (the latter only in diabetic patients) as previously described (24). The study was performed according to the Helsinki Declaration, and the protocol was approved by the local ethical committee. All subjects provided written informed consent.

Genomic DNA was extracted from peripheral blood according to standard procedures. The –866G/A polymorphism in the UCP2 gene was determined by digesting PCR products with restriction enzyme MluI (Invitrogen Life Technologies, Inc., San Diego, CA) as previously described (14). The PPAR2 P12A polymorphism was screened by dideoxy single-base extension of an unlabeled primer, according to the manufacturer instructions (ABI PRISM SNaPshot Multiplex Kit 4323151, Applied Biosystems, Foster City, CA) as previously described (25).

Statistical analyses

Data are expressed as the mean ± SD. Categorical variables and continuous ones were, respectively, compared by ² test and one-way ANOVA. Logistic regression analysis was used to assess the extent to which the –866G/A polymorphism or the P12A variant of the PPAR2 gene was associated with T2D. The same analysis was used to model the effect of each single polymorphism and their interaction on the risk of T2D. P values for the combined effect of the two SNPs on diabetes risk were also assessed through permutation analysis (26) of 1000 random replicates using an SAS macro language routine written by one of the authors.

As expected, although recruited within the same age range (i.e. 35–76 yr), controls were younger and leaner than T2D patients; therefore, when indicated, logistic regression models are adjusted for age and body mass index (BMI).

All analyses were performed using the SPSS software program version 12.0 for Windows (SPSS, Inc., Chicago, IL), and SAS (SAS release 8.2, 1999–2001, SAS Institute, Inc., Cary, NC).

	Results

Top Abstract Introduction Subjects and Methods Results Discussion References

 
The proportion of individuals carrying the three possible genotypes (–866G/G, –866G/A, and –866A/A) was significantly different between controls and T2D patients, with a trend toward a progressively reduced risk of T2D from heterozygous to homozygous subjects for the –866A allele (Table 3). Overall, a significant association of the UCP2 –866G/A genotype with T2D risk was observed [odd ratio (OR), 0.69; 95% confidence interval (CI), 95% 0.51–0.93; P < 0.015; age, gender, and BMI adjusted]. Accordingly, the resulting population risk attributable to the UCP2 –866G/G genotype (i.e. the excess rate of disease in the studied population attributable to this genotype) was approximately 12%.

View this table: [in this window] [in a new window]   TABLE 4. Distribution of UCP2 –866 G/A and PPARP12A polymorphisms in T2D patients and controls

Genotype distributions for both UCP2 and PPAR2 genotypes were in Hardy-Weinberg equilibrium in both cases (UCP2, P = 0.32; PPAR2, P = 0.42) and controls (UCP2, P = 0.63; PPAR2, P = 1.0) with the following allele frequencies: UCP2 G allele, 71% in cases and 65% in controls; UCP2 A allele, 29% in cases and 35% in controls; PPAR2 P allele, 93% in cases and 94% in controls; and PPAR2 A allele, 7% in cases and 6% in controls.

To test for population stratification, 39 genome-widely distributed unlinked polymorphic microsatellite loci from randomly selected 133 T2D patients and 115 controls were genotyped. Both the distribution of allele frequencies (as calculated by the Microsoft Excel microsatellite toolkit, http://oscar.gen.tcd.ie/sdepark/ms-toolkit/, and compared by ² analysis; data not shown) and the nonparametric method analysis of molecular variance, using Arlequin software for population genetics data analysis (27) (data not shown), suggested the lack of differential genetic admixture between cases and controls.

	Discussion

Top Abstract Introduction Subjects and Methods Results Discussion References

 
This case-control study indicates that in our population, the UCP2 –866A allele is associated with a reduced risk of T2D. A trend toward a progressively reduced risk of T2D from heterozygous to homozygous subjects for the –866A allele was observed. Conversely, an approximately 12% population risk of T2D was attributable to the UCP2 –866G/G genotype. Similar data have been obtained in a previous case-control study where the –866A allele was associated with reduced risk of T2D both when individually analyzed and when considered in combination with two additional variants of the same gene that were not associated per se with T2D (i.e. the Ala⁵⁵Val in the coding region and the 45-bp insertion/deletion in the 3'-untranslated region) (13).

The UCP2 –866A allele has been previously associated with decreased risk of obesity (11), which, in turn, might explain the reduced risk of T2D we report in this study. However, no differences in BMI were observed across the three genotype groups in controls or T2D patients, making it unlikely that in our population the protective effect of the UCP2 –866A allele on the risk of T2D may act through changes in adiposity. The UCP2 –866A allele has been variably associated with both increased (12) and decreased (13) UCP2 mRNA levels in human tissues. Similarly, UCP2 overexpression has been reported to either increase (7) or decrease (5, 6) insulin secretion in rodent pancreatic islets. It is therefore possible that the protective effect on the risk of T2D of the UCP2 –866A allele may act through the modulation of UCP2 expression in pancreatic islets. As an alternative explanation, the UCP2 –866G/A SNP might have no effect per se on the risk of T2D; rather, it may represent only a marker in linkage disequilibrium with another, causative, genetic variant(s). In fact, as inferred from HapMap genotype data from Caucasian populations, the –866G/A SNP lies in a 17-kb block covering the entire gene and its flanking sequences. In this block, the linkage disequilibrium remains high from 5' upstream SNPs such as rs591758 (D' = 1.0; r² = 0.89) to more distal SNPs such as (Ala⁵⁵Val)rs660339 (D' = 1.0; r² = 0.83) and even farther beyond (data not shown). Having such a central position and such a high r² values, in comparison with other SNPs (rs591758 vs. rs660339 has D' = 1.0 and r² = 0.73), we believe that –866G/A is a very informative SNP for the entire UCP2 gene.

Whatever the mechanisms underlying the reported association, our results are in agreement with previous findings showing a protective effect on the risk of T2D for the A allele (13), but are the opposite of those obtained among obese individuals (12). An intriguing possibility for partly explaining some of these inconsistencies is that the contribution of the UCP2 –866G/A SNP to T2D risk may be different in different samples depending on different genetic background. By reanalyzing our data according to the PPAR2 P12A genotype, the risk of T2D for subjects carrying the UCP2 –866G/G genotype was significantly increased in the PPAR2 P12/P12 homozygous subjects, whereas no effect was observed in individuals carrying the PPAR2 A12 variant. Although no significant interaction (P = 0.16, by logistic regression analysis) was obtained with our present sample size, and we, therefore, cannot conclude about gene-gene interaction, our present data may serve the function of hypothesis-generating to be tested in larger samples. In fact, this study clearly underlines the problem of trying to investigate interaction between genes whose genotype frequencies are rather rare and indicate the need for very large samples to be recruited for this purpose. Although the final net effect on insulin secretion has been controversial (20, 21, 22, 23), several studies have clearly demonstrated that PPAR2 induces UCP2 up-regulation in rat pancreatic islets (19, 20). In humans, two putative PPAR2 response elements with a DR1 half-site (AGGTCA), one of which located in the close proximity to the –866G/A SNP, have been identified, thus suggesting a potential regulation of UCP2 transcription by PPAR2 (28). All of these data make the possibility of a combined effect of the two genes on the risk of T2D a likely one. It is worth noting that while our manuscript was in preparation, a significant interaction on the risk of T2D was reported among Asians between two different polymorphisms of the same genes (i.e. the UCP2 Ala⁵⁵Val variant and the silent CT substitution in the exon 6 of PPAR2 gene (29).

In case-control studies, population stratification bias may occur and may cause false positive results (30). Because the association between this SNP and T2D has been reported in other populations (12, 13), we believe this risk is minimized in our study. In addition, the distribution of polymorphic microsatellite loci in subgroups of randomly selected T2D patients and controls suggests the lack of differential genetic admixture between these two groups (data not shown). Although, as indicated by very recent data (31), the number of individuals studied for this analysis may be insufficient to draw firm conclusions, this finding is compatible with the lack of a population stratification bias in our study.

In conclusion, in the Gargano Caucasian population, the –866 A allele in the promoter region of the UCP2 gene is associated with a reduced risk of T2D. Conversely, an approximately 12% population risk of T2D was attributable to the –866G/G genotype. Additional studies in larger samples also investigating the concomitant role of other potential diabetogenes are likely to help in understanding the role of the UCP2 gene in polygenic control of T2D.

	Acknowledgments

 
We thank C. Cisternino (B.S.) and G. Fini (B.S.) for technical support. We also thank Dr. G. Sesti (University of Catanzaro, Catanzaro, Italy) for kindly providing us with control sequence samples, and Dr. Vittorio Tassi (CSS Institute, San Giovanni Rotondo, Italy) for helpful discussion.

	Footnotes

 
This work was supported by Italian Ministry of Health Grants Ricerca Finalizzata 2002 (to V.T.) and Ricerca Corrente 2003 (to R.D.P.).

First Published Online November 23, 2004

Abbreviations: BMI, Body mass index; CI, confidence interval; OR, odd ratio; PPAR, peroxisomal proliferator-activated receptor; SNP, single nucleotide polymorphism; T2D, type 2 diabetes; UCP2, uncoupling protein-2.

Received June 7, 2004.

Accepted November 10, 2004.

	References

Top Abstract Introduction Subjects and Methods Results Discussion References

 

1. King H, Aubert RE, Herman WH 1998 Global burden of diabetes 1995–2025. Diabetes Care 21:1414–1431[Abstract]
2. Kahn SE 2003 The relative contribution of insulin resistance and ß-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3–19[CrossRef][Medline]
3. Almind K, Doria A, Kahn CR 2001 Putting the genes for type II diabetes on the map. Nat Med 3:277–279
4. O’Railly S 2001 Uncoupling protein 2: adiposity angel and diabetes devil? Nat Med 7:770–772[CrossRef][Medline]
5. Chan CB, MacDonald PE, Saleh MC, Johns DC, Marban E, Wheeler MB 1999 Overexpression of uncoupling protein 2 inhibits glucose-stimulated insulin secretion from rat islets. Diabetes 48:1482–1486[Abstract]
6. Zhang CY, Baffy G, Perret G, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, Zheng X, Wheeler MB, Shulman GI, Chan CB, Lowell BB 2001 Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, ß cell dysfunction, and type 2 diabetes. Cell 105:745–755[CrossRef][Medline]
7. Wang MY, Shimabukuro M, Lee Y, Trinh KY, Chen JL, Newgard CB, Unger RH 1999 1999 Adenovirus-mediated overexpression of uncoupling protein-2 in pancreatic islets of Zucker diabetic rats increases oxidative activity and improves ß-cell function. Diabetes 48:1020–1025[Abstract]
8. Kaisaki PJ, Woon PY, Wallis RH, Monaco AP, Lathrop M, Gauguier D 1998 Localization of tub and uncoupling proteins (Ucp) 2 and 3 to a region of rat chromosome 1 linked to glucose intolerance and adiposity in the Goto-Kakizaki (Gk) type 2 diabetic rat. Mamm Genome 9:910–912[CrossRef][Medline]
9. Ghosh S, Watanabe RM, Valle TT, Hauser ER, Magnuson VL, Langefeld CD, Ally DS, Mohlke KL, Silander K, Kohtamäki K, Chines P, Balow Jr J, Birznieks G, Chang J, Eldridge W, Erdos MR, Karanjawala ZE, Knapp JI, Kudelko K, Martin C, Morales-Mena A, Musick A, Musick T, Pfahl C, Porter R, Rayman JB, Rha D, Segal L, Shapiro S, Sharaf R, Shurtleff B, So A, Tannenbaum J, Te C, Tovar J, Unni A, Welch C, Whiten R, Witt A, Blaschack-Harvan J, Douglas JA, Duren WL, Epstein MP, Fingerlin TE, Kaleta HS, Lange EM, Li C, McEachin RC, Stringham HM, Trager E, White PP, Eriksson J, Toivanen L, Vidgren G, Nylund SJ, Tuomilehto-Wolf E, Ross EH, Demirchyan E, Hagopian WA, Buchanan TA, Tuomilehto J, Bergman RN, Collins FS, Boehnke M 2000 The Finland-United States Investigation of Non-Insulin-Dependent Diabetes Mellitus Genetics (FUSION) study I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet 67:1174–1185[Medline]
10. Dalgaard LT, Pedersen O 2001 Uncoupling proteins: functional characteristics and role in the pathogenesis of obesity and type 2 diabetes. Diabetologia 44:946–965[CrossRef][Medline]
11. Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F, Ladurner G, Hell E, Strosberg AD, Patsch JR, Krempler F, Patsch W 2001 A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 28:178–183[CrossRef][Medline]
12. Krempler F, Esterbauer H, Weitgasser R, Ebenbichler C, Patsch JR, Miller K, Xie M, Linnemayr V, Oberkofler H, Patsch W 2002 A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans. Diabetes 51:3331–3335[Abstract/Free Full Text]
13. Wang H, Chu WS, Lu T, Hasstedt SJ, Kern PA, Elbein SC 2004 Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion. Am J Physiol 286:E1–E7
14. Sesti G, Cardellini M, Marini MA, Frontoni S, D’Adamo M, Del Guerra S, Lauro D, De Nicolais P, Sbraccia P, Del Prato S, Gambardella S, Federici M, Marchetti P, Lauro R 2003 A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. Diabetes 52:1280–1283[Abstract/Free Full Text]
15. Stumvoll M, Haring H 2002 The peroxisome proliferator-activated receptor-2 Pro¹²Ala polymorphism. Diabetes 51:2341–2347[Abstract/Free Full Text]
16. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J 1998 A Pro¹²Ala substitution in PPAR2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287[CrossRef][Medline]
17. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M 2000 Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator activated receptor-2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 268:178–182[CrossRef][Medline]
18. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES 2000 The common PPAR Pro¹²Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80[CrossRef][Medline]
19. Shimabukuro M, Zhou YT, Lee Y, Unger RH 1997 Induction of uncoupling protein-2 mRNA by troglitazone in the pancreatic islets of Zucker diabetic fatty rats. Biochem Biophys Res Commun 237:359–361[CrossRef][Medline]
20. Patane‘ G, Anello M, Piro S, Vigneri R, Purrello F, Rabuazzo AM 2002 Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor- inhibition. Diabetes 51:2749–2756[Abstract/Free Full Text]
21. Shimabukuro M, Zhou YT, Lee Y, Unger RH 1998 Troglitazone lowers islet fat and restores ß cell function of Zucker diabetic fatty rats. J Biol Chem 273:3547–3550[Abstract/Free Full Text]
22. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC 1998 Peroxisome proliferator-activated receptor- agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47:1326–1334[Abstract]
23. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S 2004 Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPAR2 in the modulation of insulin secretion. Am J Physiol 286:E560–E567
24. Di Paola R, Frittitta L, Miscio G, Bozzali M, Baratta R, Centra M, Spampinato D, Santagati MG, Ercolino T, Cisternino C, Soccio T, Mastroianno S, Tassi V, Almgren P, Pizzuti A, Vigneri R, Trischitta V 2002 A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet 70:806–812[CrossRef][Medline]
25. Baratta R, Di Paola R, Spampinato D, Fini G, Marucci A, Coco A, Vigneri R, Frittitta L, Trischitta V 2003 Evidence for genetic epistasis in human insulin resistance: the combined effect of PC-1 (K121Q) and PPAR2 (P12A) polymorphisms. J Mol Med 81:718–723[CrossRef][Medline]
26. Efron B, Tibshirani RJ 1993 An introduction to the bootstrap, chapt 15. New York: Chapman, Hall; 202–218
27. Schneider S, Roessli D, Excoffier L 2000 Arlequin: a software for population genetics data analysis, version 2.000. Geneva: University of Geneva
28. Tu N, Chen H, Winnikes U, Reinert I, Marmann G, Pirke KM, Lentes KU 1999 Molecular cloning and functional characterization of the promoter region of the human uncoupling protein-2 gene. Biochem Biophys Res Commun 265:326–334[CrossRef][Medline]
29. Cho YM, Ritchie MD, Moore JH, Park JY, Lee KU, Shin HD, Lee HK, Park KS 2004 Multifactor-dimensionality reduction shows a two-locus interaction associated with type 2 diabetes mellitus. Diabetologia 47:549–554[CrossRef][Medline]
30. Lander ES, Schork NJ 1994 Genetic dissection of complex traits. Science 265:2037–2048[Abstract/Free Full Text]
31. Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N, Gabriel SB, Topol EJ, Smoller JW, Pato CN, Pato MP, Petryshen TL, Kolonel LN, Lander ES, Sklar P, Henderson B, Hirschhorn JN, Altshuler D 2004 Assessing the impact of population stratification on genetic association study. Nat Genet 36:388–393[CrossRef][Medline]

This article has been cited by other articles:

				Y.-H. Hsu, T. Niu, Y. Song, L. Tinker, L. H. Kuller, and S. Liu Genetic Variants in the UCP2-UCP3 Gene Cluster and Risk of Diabetes in the Women's Health Initiative Observational Study Diabetes, April 1, 2008; 57(4): 1101 - 1107. [Abstract] [Full Text] [PDF]

				E. Chevillotte, M. Giralt, B. Miroux, D. Ricquier, and F. Villarroya Uncoupling Protein-2 Controls Adiponectin Gene Expression in Adipose Tissue Through the Modulation of Reactive Oxygen Species Production Diabetes, April 1, 2007; 56(4): 1042 - 1050. [Abstract] [Full Text] [PDF]

				H. Oberkofler, K. Klein, T. K. Felder, F. Krempler, and W. Patsch Role of Peroxisome Proliferator-Activated Receptor-{gamma} Coactivator-1{alpha} in the Transcriptional Regulation of the Human Uncoupling Protein 2 Gene in INS-1E Cells Endocrinology, February 1, 2006; 147(2): 966 - 976. [Abstract] [Full Text] [PDF]

				X. Yu, D. R. Jacobs Jr, P. J. Schreiner, M. D. Gross, M. W. Steffes, and M. Fornage The Uncoupling Protein 2 Ala55Val Polymorphism Is Associated with Diabetes Mellitus: The CARDIA Study Clin. Chem., August 1, 2005; 51(8): 1451 - 1456. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bulotta, A. Articles by Trischitta, V. Search for Related Content PubMed PubMed Citation Articles by Bulotta, A. Articles by Trischitta, V. Related Collections Diabetes and Insulin